Kidney disease

Hiromi I. Wettersten, Robert H Weiss

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Owing to the high suitability of urine for such studies and the ready accessibility of the urinary tract by means of its principal biofluid, there have been a growing number metabolomic studies that attempted to discover biomarkers and therapeutic targets for various kidney diseases. While there has been moderate success in this endeavor, future work will need to focus on extensive validation efforts to enable these potential markers and targets to be translated to the clinic for early disease diagnosis, therapies, and elucidation of new pathophysiological insights.

Original languageEnglish (US)
Title of host publicationGlobal Metabolic Profiling: Clinical Applications
PublisherFuture Medicine Ltd.
Pages124-139
Number of pages16
ISBN (Electronic)9781909453616
ISBN (Print)9781909453623
DOIs
StatePublished - Jan 1 2014

Fingerprint

Biomarkers
Metabolomics

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Wettersten, H. I., & Weiss, R. H. (2014). Kidney disease. In Global Metabolic Profiling: Clinical Applications (pp. 124-139). Future Medicine Ltd.. https://doi.org/10.4155/EBO.13.351

Kidney disease. / Wettersten, Hiromi I.; Weiss, Robert H.

Global Metabolic Profiling: Clinical Applications. Future Medicine Ltd., 2014. p. 124-139.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wettersten, HI & Weiss, RH 2014, Kidney disease. in Global Metabolic Profiling: Clinical Applications. Future Medicine Ltd., pp. 124-139. https://doi.org/10.4155/EBO.13.351
Wettersten HI, Weiss RH. Kidney disease. In Global Metabolic Profiling: Clinical Applications. Future Medicine Ltd. 2014. p. 124-139 https://doi.org/10.4155/EBO.13.351
Wettersten, Hiromi I. ; Weiss, Robert H. / Kidney disease. Global Metabolic Profiling: Clinical Applications. Future Medicine Ltd., 2014. pp. 124-139
@inbook{702778c140fc4a379b956b149e5090fa,
title = "Kidney disease",
abstract = "Owing to the high suitability of urine for such studies and the ready accessibility of the urinary tract by means of its principal biofluid, there have been a growing number metabolomic studies that attempted to discover biomarkers and therapeutic targets for various kidney diseases. While there has been moderate success in this endeavor, future work will need to focus on extensive validation efforts to enable these potential markers and targets to be translated to the clinic for early disease diagnosis, therapies, and elucidation of new pathophysiological insights.",
author = "Wettersten, {Hiromi I.} and Weiss, {Robert H}",
year = "2014",
month = "1",
day = "1",
doi = "10.4155/EBO.13.351",
language = "English (US)",
isbn = "9781909453623",
pages = "124--139",
booktitle = "Global Metabolic Profiling: Clinical Applications",
publisher = "Future Medicine Ltd.",
address = "United Kingdom",

}

TY - CHAP

T1 - Kidney disease

AU - Wettersten, Hiromi I.

AU - Weiss, Robert H

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Owing to the high suitability of urine for such studies and the ready accessibility of the urinary tract by means of its principal biofluid, there have been a growing number metabolomic studies that attempted to discover biomarkers and therapeutic targets for various kidney diseases. While there has been moderate success in this endeavor, future work will need to focus on extensive validation efforts to enable these potential markers and targets to be translated to the clinic for early disease diagnosis, therapies, and elucidation of new pathophysiological insights.

AB - Owing to the high suitability of urine for such studies and the ready accessibility of the urinary tract by means of its principal biofluid, there have been a growing number metabolomic studies that attempted to discover biomarkers and therapeutic targets for various kidney diseases. While there has been moderate success in this endeavor, future work will need to focus on extensive validation efforts to enable these potential markers and targets to be translated to the clinic for early disease diagnosis, therapies, and elucidation of new pathophysiological insights.

UR - http://www.scopus.com/inward/record.url?scp=84957055979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957055979&partnerID=8YFLogxK

U2 - 10.4155/EBO.13.351

DO - 10.4155/EBO.13.351

M3 - Chapter

AN - SCOPUS:84957055979

SN - 9781909453623

SP - 124

EP - 139

BT - Global Metabolic Profiling: Clinical Applications

PB - Future Medicine Ltd.

ER -